VP, Translational Biology
Dr. Cicmil brings nearly 17 years of drug discovery experience across pre-clinical and early stage clinical development programs, biology, partnering and R&D strategy. He spent 15 years in positions of increasing responsibility within R&D, with companies such as Merck, Astra Zeneca and GE Healthcare. As a Director of Pharmacology at Merck, Dr. Cicmil led multifunctional teams and was responsible for delivery of Immunology and Immuno-Oncology project portfolios and translational pharmacology data supporting early clinical studies for small molecules, peptides and biologics. During his tenure in pharma, Dr. Cicmil built strong groups and provided scientific leadership, as well as leading a number of multifunctional projects, advancing them through all stages of pre-clinical discovery into clinic. Most recently at the Merck Innovation Hub, Dr. Cicmil was leading Search & Evaluation efforts for in-licensing opportunities and partnership generation for Immuno-Oncology, Immunology and Ophthalmology therapy areas, resulting in several collaboration/partnerships, including the Phase 2 Diabetic Macular Edema asset with KalVista and selective targeting of T cell subsets for the treatment of autoimmune disease with Cue Biopharma totaling over $1billion.
Dr. Cicmil holds a Ph.D. in Molecular Pharmacology from the University of Reading, UK and a BSc in Molecular Biology from Kings College, London. Prior to joining the pharmaceutical industry, Dr. Cicmil was a postdoctoral fellow at the Cancer Research UK. Milenko has co-authored a number of scientific publications, reviews and abstracts.